Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a ...

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...

A newer brain stimulation therapy matched ECT for depression while causing less memory loss, offering a potential option for patients concerned about cognitive side effects.

A new analysis included more than 110,000 adults with major depressive disorder (MDD) and treatment-resistant depression (TRD). Patients with TRD had total healthcare costs 1.5 times higher than those ...

Treatment with oral semaglutide (Rybelsus) significantly improved motivation measures in patients with major depressive ...

Rates of depression notably spiked during the pandemic. But even though life has largely returned to normal, we’re still in a mental health crisis. In 2023, the U.S. Surgeon General declared an ...

Women with MDD who did not use antidepressants had more than twice the risk of breast cancer recurrence as women without MDD. Women with breast cancer who also have major depressive disorder (MDD) ...

Major depression fluctuates during and after pregnancy but has the highest prevalence two weeks after giving birth, a ...

Why do mental health diagnoses so often overlap? New genetic research reveals shared roots and points toward more effective ...

Scientific review highlights the prevalence of major depressive disorders during the period, identifying its most risky stage ...